Biomarkers of cardiotoxicity in multiple myeloma

Biomarkers of cardiotoxicity in multiple myeloma

User Photo
VJHemOnc

4 years
308 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about biomarkers of cardiotoxicity in multiple myeloma in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.
Up Next Autoplay